MOTS-c vs SS-31: Research Comparison | Peptide Intel Hub

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of the mitochondrial genome. In research models it has been characterised as a signalling peptide that influences nuclear gene expression and metabolic homeostasis, particularly through AMPK-axis activation.

SS-31 (elamipretide) is a synthetic four-amino-acid peptide (D-Arg-2',6'-dimethylTyr-Lys-Phe-NH2) that localises selectively to the inner mitochondrial membrane and binds to cardiolipin. The cardiolipin interaction is the proposed mechanism for its mitochondrial-protective effects in published research.

MOTS-c does not act through a single canonical receptor in the conventional sense — its proposed mechanism centres on intracellular AMPK-axis activation and downstream effects on nuclear metabolic gene expression.

SS-31 does not act through a cell-surface receptor either; its proposed mechanism is the direct interaction with cardiolipin at the inner mitochondrial membrane, stabilising mitochondrial cristae structure and preserving electron-transport-chain function in research models.

MOTS-c is a 16-residue peptide with a short native half-life; research protocols typically use daily or sub-daily cadences with bacteriostatic-water reconstitution and refrigerated in-use storage.

SS-31 is a small tetrapeptide with sub-cellular targeting and a similarly short native half-life. Research cadences are typically daily; the small molecular size simplifies penetration in cell-culture models compared with larger peptides.

MOTS-c is widely used in metabolic, exercise-physiology, insulin-sensitivity and longevity research models. The AMPK-axis activation profile makes it a common comparator against other metabolic-axis research compounds.

SS-31 is the leading research compound for mitochondrial-membrane and cardiolipin-interaction studies. It is widely used in ischaemia-reperfusion, neurodegeneration and mitochondrial-dysfunction research models where preserving electron-transport-chain function is the experimental endpoint.

Both MOTS-c and SS-31 should only be sourced from suppliers that use independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds should be published by the supplier so a researcher can audit the analytical detail. The /trust/how-to-read-a-coa reference walks through every field on a modern COA.

Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a two-month (60-day) in-use stability window under refrigeration. SS-31 is particularly sensitive to repeat freeze-thaw cycling — aliquot before any freeze.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both MOTS-c and SS-31 benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose MOTS-c when the protocol targets metabolic, exercise-physiology or AMPK-axis signalling outcomes. Researchers choose SS-31 when the protocol targets the inner mitochondrial membrane directly — cardiolipin interaction, electron-transport-chain preservation, ischaemia-reperfusion models — and when a small-molecule pharmacokinetic profile is preferred over a longer signalling peptide.

For multi-compound comparator studies, reputable suppliers can often reserve matched-batch inventory of both MOTS-c and SS-31 against a project timeline so the experimental panel is sourced under a single analytical specification window.

Mitochondria, traditionally recognized as the cell's powerhouses, are increasingly understood for their role as signaling hubs, communicating with the nucleus to maintain cellular balance (PMID 25738459, PMID 29983246). This complex interplay involves mitochondrial-derived peptides (MDPs), short amino acid chains encoded within mitochondrial DNA that exert diverse biological effects. Among these, MOTS-c and SS-31 (elamipretide) have emerged as significant subjects of scientific inquiry, each exhibiting unique mechanisms and potential therapeutic applications (PMID 25738459, PMID 39940712). While both peptides are linked to mitochondrial function, their specific roles, targets, and demonstrated efficacies diverge, warranting a closer look at their individual profiles.

MOTS-c, a 16-amino-acid peptide encoded by a short open reading frame within the mitochondrial 12S rRNA, functions as a retrograde mitochondrial signal (PMID 25738459, PMID 36761202). It is known to regulate insulin sensitivity and metabolic homeostasis, primarily targeting skeletal muscle (PMID 25738459). Beyond metabolism, MOTS-c influences oxidative and toxic stress, inflammation, autophagy, cell death, and immune responses (PMID 42243958). It can translocate to the nucleus to regulate gene expression, particularly under metabolic stress, in an AMPK-dependent manner (PMID 29983246). This dual localization and broad impact underscore its multifaceted role in cellular physiology (PMID 29983246, PMID 42243958).

SS-31, also known as elamipretide or Bendavia, is a mitochondrion-targeted tetrapeptide designed to selectively bind to cardiolipin, a lipid found in the inner mitochondrial membrane (PMID 39940712). This binding stabilizes mitochondrial cristae structure, reduces oxidative stress, and enhances adenosine triphosphate (ATP) production (PMID 39940712). Its unique structure facilitates uptake into various cell types and highly selective mitochondrial targeting (PMID 39940712). SS-31's primary actions revolve around improving mitochondrial bioenergetics and minimizing oxidative stress, making it a focus for disorders linked to mitochondrial dysfunction (PMID 39940712).

MOTS-c plays a significant role in metabolic homeostasis, with its primary target organ appearing to be skeletal muscle (PMID 25738459). Its cellular actions inhibit the folate cycle and its tethered de novo purine biosynthesis, leading to AMPK activation (PMID 25738459). In animal studies, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity in mice (PMID 25738459). This suggests that MOTS-c may actively regulate metabolic homeostasis at both cellular and organismal levels (PMID 25738459). Furthermore, MOTS-c has been shown to improve glucose metabolism in skeletal muscle, indicating its potential benefits for conditions such as diabetes and obesity (PMID 36761202).

In gestational diabetes mellitus (GDM) mouse models, MOTS-c significantly alleviated hyperglycemia, improved insulin sensitivity and glucose tolerance, and reduced birth weight and offspring death induced by GDM (PMID 34798268). It also activated insulin sensitivity in the skeletal muscle of GDM mice and elevated glucose uptake in vitro (PMID 34798268). Additionally, MOTS-c was found to protect pancreatic β-cells from streptozotocin-mediated injury in these studies (PMID 34798268). These findings highlight MOTS-c's potential as a promising strategy for GDM treatment (PMID 34798268).

MOTS-c has been demonstrated to augment muscle mitochondrial bioenergetic performance through reliance on both the transcriptional coactivator PGC-1α and cellular energy-sensing kinase AMPK in transgenic mouse strains (PMID 41520850). These effects appear to be exerted without a clear impact on mitochondrial respiratory protein content, suggesting intrinsic mitochondrial changes rather than changes in volume (PMID 41520850). While MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner in mice, human studies showed no change in the arterio-venous difference of MOTS-c during one-legged knee extensor exercise, suggesting that skeletal muscle may not be the source of circulating MOTS-c in response to exercise (PMID 41520850).

Elamipretide (SS-31) is a mitochondrion-targeted antioxidant that directly binds to cardiolipin, stabilizing the inner mitochondrial membrane and reducing oxidative stress (PMID 39940712). In a study using a lipopolysaccharide (LPS)-induced memory impairment mouse model, elamipretide not only provided protective effects against mitochondrial dysfunction and oxidative stress but also facilitated the regulation of brain-derived neurotrophic factor (BDNF) signaling (PMID 31747905). This included the reversal of important synaptic-signaling proteins and increased synaptic structural complexity (PMID 31747905). These findings suggest that elamipretide has therapeutic potential in preventing damage from oxidative stress and neuroinflammation, particularly in conditions like perioperative neurocognitive disorders (PND) in mice (PMID 31747905).

Elamipretide (SS-31) improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT) (PMID 37462785). In aged muscle mitochondria, elamipretide treatment increased ADP sensitivity and rescued muscle force and heart systolic function in vivo (PMID 37462785). Although protein abundance in the ADP/ATP transport and synthesis pathway was unchanged, elamipretide treatment decreased protein S-glutathionylation, including that of ANT (PMID 37462785). This research supports the hypothesis that elamipretide improves ANT function in aging and links mitochondrial ADP sensitivity to physiological function (PMID 37462785).

MOTS-c also exhibits antioxidant properties, reducing mitochondrial reactive oxygen species (ROS) emission and ROS-related protein damage, indicating substantial alleviation of cellular oxidative stress in transgenic mouse strains (PMID 41520850). In rat models of lung ischemia-reperfusion injury (LIRI), MOTS-c attenuated lung injury by reducing oxidative damage, inflammation, and mortality (PMID 40403491). Mechanistically, it acts via ROS-CK2A-MYH9 signaling to activate nuclear antioxidant defenses, involving direct interaction with promoters of antioxidant genes like HMOX1 and NQO1 (PMID 40403491). This suggests MOTS-c functions as a dual-action molecule in mitigating oxidative stress and inflammatory responses (PMID 40403491).

Elamipretide (SS-31) attenuates idiopathic pulmonary fibrosis (IPF) by inhibiting the Nrf2-dependent NLRP3 inflammasome in macrophages in a bleomycin (BLM)-induced mouse model (PMID 38136142). In these studies, SS-31 treatment significantly suppressed BLM-induced pulmonary fibrosis and inflammation, leading to improved histological changes and decreased extracellular matrix deposition and inflammatory cytokines release (PMID 38136142). The expression percentage of IL-1β and IL-18 was downregulated by more than half with SS-31 treatment (PMID 38136142). Mechanistically, SS-31 inhibited IL-33- or LPS/IL-4-induced production of IL-1β and IL-18 in macrophages by suppressing NLRP3 inflammasome activation (PMID 38136142). The Nrf2 pathway was dramatically upregulated along with improved mitochondrial function after SS-31 treatment in activated macrophages and BLM-induced mice, suggesting its role in SS-31's protective effects (PMID 38136142).

In the context of heart failure with preserved ejection fraction (HFpEF) in a rat model, elamipretide improved whole muscle and single-fiber contractile function and titin phosphorylation, while preventing atrophy development (PMID 42290373). These improvements were associated with improved mitochondrial function, presumably through cardiolipin-mediated improvements in oxidative phosphorylation (PMID 42290373). This highlights cardiolipin stabilization as a key modulator of mitochondrial and contractile function in HFpEF, identifying elamipretide as a promising therapeutic approach for skeletal muscle dysfunction in this condition (PMID 42290373).

MOTS-c demonstrates anti-inflammatory and disease-modulating roles across various conditions. In ovarian cancer (OC) patients, MOTS-c levels were found to be reduced in both serum and tumor tissues, correlating with poor prognosis (PMID 39321430). Exogenous MOTS-c inhibited proliferation, migration, and invasion of OC cells, and induced cell cycle arrest and apoptosis in vitro (PMID 39321430). Importantly, MOTS-c displayed a significant anti-tumor effect on OC growth without systemic toxicity in vivo, suggesting its potential as a therapeutic target for this malignancy (PMID 39321430). Additionally, MOTS-c attenuates mitochondrial dysfunction, pyroptosis, and cartilage degradation in osteoarthritis via an Nrf2-dependent mechanism in a murine osteoarthritis model (PMID 41043625). Exogenous supplementation of MOTS-c improved mitochondrial dysfunction, inhibited inflammatory body activation, rescued chondrocyte pyroptosis, and promoted the expression of extracellular matrix components, while suppressing matrix metalloproteinase production (PMID 41043625). Imaging and histopathological analysis confirmed that MOTS-c effectively delayed articular cartilage degeneration and ameliorated osteoarthritis progression in vivo (PMID 41043625).

For MOTS-c, clinical observations suggest a possible link between its levels and human cancer, with reduced serum and tumor tissue levels in ovarian cancer patients associated with poor prognosis (PMID 39321430). In clinical studies, serum MOTS-c increments within 24 hours post-cardiopulmonary bypass (ΔMOTS-c) outperformed traditional biomarkers in predicting ARDS incidence, with multivariate models incorporating ΔMOTS-c achieving superior discriminative power (AUC = 0.885) (PMID 40403491). This positions MOTS-c as a potential prognostic biomarker for CPB-related complications (PMID 40403491). Furthermore, circulating MOTS-c levels are suggested to be reduced in different forms of acute respiratory distress, while exogenous administration attenuates lung injury in preclinical models (PMID 42243958). In chronic respiratory diseases like COPD, obstructive sleep apnea, and asthma, decreased MOTS-c concentrations reflect severe mitochondrial dysfunction and reduced cytoprotective capacity (PMID 42243958). Preliminary observations suggest increased MOTS-c levels in lung cancer, possibly related to NRF2-mediated antioxidant responses, though this requires further validation (PMID 42243958).

For SS-31, several clinical trials such as PROGRESS-HF, TAZPOWER, MMPOWER-3, and ReCLAIM elaborate on preclinical findings and highlight its significant therapeutic potential (PMID 39940712). Elamipretide is also recognized as a potential candidate for age-related macular degeneration (AMD) therapy (PMID 34572131). The peptide's ability to improve mitochondrial function and inhibit oxidative stress in models of heart failure, neurodegeneration, ischemia-reperfusion injury, metabolic syndromes, and muscle atrophy and weakness underscores its broad applicability (PMID 39940712). A liposomal composite hydrogel containing elamipretide (SS-31) improved cardiac function in a rat MI model by scavenging excess ROS, improving mitochondrial dysfunction, and promoting angiogenesis (PMID 35848825).

However, current evidence on the clinical application of MOTS-c is less developed. While it has been shown to improve glucose metabolism and potentially benefit diseases like diabetes, obesity, and aging in preclinical models, an effective method of applying MOTS-c in the clinic has not yet been developed (PMID 36761202). Well-designed translational and multicenter clinical studies are needed to determine if modulation or supplementation of MOTS-c can influence disease progression and clinical outcomes in inflammatory lung diseases (PMID 42243958). For both peptides, further research is required to expand their application to other diseases involving mitochondrial dysfunction and to investigate their long-term efficacy and safety (PMID 39940712, PMID 42243958).

MOTS-c interacts with LARS1 and promotes its ubiquitination and proteasomal degradation (PMID 39321430). USP7 was identified as a deubiquitinase of LARS1, and MOTS-c can attenuate USP7-mediated LARS1 deubiquitination by competing with USP7 for binding to LARS1 (PMID 39321430). This mechanism underlies its inhibitory effect on ovarian cancer cell proliferation, migration, and invasion (PMID 39321430). MOTS-c also translocates to the nucleus following metabolic stress, regulating nuclear gene expression in an AMPK-dependent manner (PMID 29983246). In the nucleus, MOTS-c regulates genes, including those with antioxidant response elements (AREs), and interacts with ARE-regulating stress-responsive transcription factors such as NRF2 (PMID 29983246). This indicates a direct role in mitonuclear communication and gene regulation (PMID 29983246).

In lung ischemia-reperfusion injury models, hypoxia-reoxygenation triggered reactive oxygen species (ROS)-dependent phosphorylation of MYH9 at Ser1943 via casein kinase II subunit alpha (CK2A), enabling MOTS-c binding to MYH9-γ-Actin complexes for nuclear transport (PMID 40403491). RNA sequencing and ChIP-seq revealed direct MOTS-c interaction with promoters of antioxidant genes (e.g., HMOX1, NQO1) (PMID 40403491). Furthermore, MOTS-c promotes muscle differentiation in vitro, interacting with STAT3 via a putative SH2 binding motif in its YIFY region to reduce STAT3 transcriptional activity, thereby enhancing myotube formation (PMID 35842023). This mechanism suggests MOTS-c as a potential therapeutic target against muscle-wasting (PMID 35842023).

Elamipretide (SS-31) selectively binds to cardiolipin, a lipid in the inner mitochondrial membrane (PMID 39940712). This binding stabilizes mitochondrial cristae structure, reduces oxidative stress, and enhances ATP production (PMID 39940712). In animal models of ischemic stroke, co-administration of SS-31 and nicotinamide mononucleotide (NMN) significantly attenuated post-ischemic brain damage and ameliorated neurological deficits, demonstrating superior effects to monotherapy (PMID 42443448). This combination therapy specifically modulated innate immune and apoptotic pathways, with a significant downregulation of TREM2 and inhibition of NF-κB (p65) activation, leading to suppressed microglial activation and reduced pro-inflammatory cytokines (PMID 42443448). SS-31@Fer-1, a combination of SS-31 and ferrostatin1, was shown to alleviate ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting, improving cardiomyocyte viability and mitochondrial integrity (PMID 39848110).

Current research on MOTS-c is expanding beyond its initial metabolic focus to include roles in cancer, inflammation, and respiratory diseases. The identification of MOTS-c levels as a potential prognostic biomarker for CPB-related complications and its dual function in activating nuclear antioxidant defenses opens new avenues for preventive strategies (PMID 40403491). Its observed anti-tumor effects in ovarian cancer models without systemic toxicity highlight its therapeutic potential for malignancy (PMID 39321430). The novel role of MOTS-c in regulating MYH9-actin-mediated mitochondrial dynamics and contributing to mitochondrial biogenesis during HBV infection presents a promising innovative approach for treating chronic hepatitis B (PMID 37788894).

For SS-31, ongoing and future research aims to expand its application to other diseases involving mitochondrial dysfunction and to thoroughly investigate its long-term efficacy and safety (PMID 39940712). Its neuroprotective properties in LPS-induced memory impairment and its role in mitigating post-ischemic brain injury in combination with NMN suggest significant potential in neurological conditions (PMID 31747905, PMID 42443448). The use of SS-31 in novel delivery systems, such as liposomal composite hydrogels for myocardial infarction, exemplifies efforts to optimize its therapeutic impact (PMID 35848825). Its recognized role as a potential candidate for age-related macular degeneration also positions it for further ophthalmic research (PMID 34572131).

Both MOTS-c and SS-31 are part of a broader class of peptides with a unique pharmacological niche, bridging small-molecule drugs and large proteins (PMID 41966639). While MOTS-c and SS-31 have undergone rigorous approval processes and demonstrate favorable outcomes in animal models for tissue repair and metabolic function, discussions around their utilization in sports medicine highlight the importance of robust human safety data (PMID 41966639). There is an acknowledged need for well-designed translational and multicenter clinical studies for MOTS-c to determine its influence on disease progression and clinical outcomes (PMID 42243958). Similarly, for SS-31, further research is key to fully realize its potential across various diseases where mitochondrial dysfunction plays a role (PMID 39940712).

• Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination. — Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2024). PMID 39321430
• The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. — Cell metabolism (2015). PMID 25738459
• MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes. — Redox biology (2025). PMID 40403491
• The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. — Cell metabolism (2018). PMID 29983246
• MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. — Free radical biology & medicine (2026). PMID 41520850
• MOTS-c promotes muscle differentiation in vitro. — Peptides (2022). PMID 35842023
• MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases. — Journal of translational medicine (2026). PMID 42243958
• MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. — Frontiers in endocrinology (2023). PMID 36761202
• MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism. — Free radical biology & medicine (2025). PMID 41043625
• Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection. — Gut (2024). PMID 37788894
• The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. — Pharmacological research (2022). PMID 34798268
• Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. — Journal of neuroinflammation (2019). PMID 31747905
• Potential Therapeutic Candidates for Age-Related Macular Degeneration (AMD). — Cells (2021). PMID 34572131
• SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. — Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2025). PMID 39848110
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. — Sports medicine (Auckland, N.Z.) (2026). PMID 41966639
• Elamipretide(SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the Nrf2-Dependent NLRP3 Inflammasome in Macrophages. — Antioxidants (Basel, Switzerland) (2023). PMID 38136142
• Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. — International journal of molecular sciences (2025). PMID 39940712
• The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT). — GeroScience (2023). PMID 37462785
• Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice. — Neurochemical research (2026). PMID 42443448
• Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model. — Circulation. Heart failure (2026). PMID 42290373
• A ROS-Responsive Liposomal Composite Hydrogel Integrating Improved Mitochondrial Function and Pro-Angiogenesis for Efficient Treatment of Myocardial Infarction. — Advanced healthcare materials (2022). PMID 35848825

Both MOTS-c and SS-31 are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on Peptide Intel Hub exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.